Clinical trial
A Non-randomized, Open-label, Phase II Study of Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not Suitable for Transplantation
NCT03373019 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Non-randomized, Open-label, Phase II Study of Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not Suitable for Transplantation
- Lead sponsor
- Fudan University
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- December 21, 2017
- Completion date
- March 1, 2021
- Enrollment
- 63 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
chidamide, cisplatin, cyclophosphamide, dexamethasone, gemcitabine, hdac inhibitor, immune system diseases, immunoproliferative disorders, lymphatic diseases, lymphoma, b-cell, lymphoma, large b-cell, diffuse, lymphoma, non-hodgkin, lymphoproliferative disorders, neoplasm by histology, neoplasms, rituximab